Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

Stereotactic body radiotherapy delays the need for long-term androgen deprivation therapy (ADT) in many men with oligometastatic prostate cancer, a study shows.

Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

We are excited to bring the Alpha DaRT technology to prostate cancer patients in the U.S.,” said Dr. Robert B. Den, Alpha Tau ...

Treatments for prostate cancers localised to the prostate have long been aimed at treating the whole prostate either by ...